PUNE, India, November 16, 2016
PUNE, India, November 16, 2016 /PRNewswire/ --
ReportsnReports.com adds "Insomnia - Pipeline Review, H2 2016" to its store providing comprehensive information on the therapeutics under development for Insomnia (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Complete report on H2 2016 pipeline review of Insomnia with 35 market data tables and 15 figures, spread across 101 pages is available at http://www.reportsnreports.com/reports/747733-insomnia-pipeline-review-h2-2016.html .
Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress and shift working.
Companies discussed in this Insomnia Pipeline Review, H2 2016 report include Actelion Ltd, Alexza Pharmaceuticals, Inc., Eisai Co., Ltd., Evotec AG, Grupo Ferrer Internacional, S.A., Heptares Therapeutics Limited, Intec Pharma Ltd, Intra-Cellular Therapies, Inc., Johnson & Johnson, Leading BioSciences, Inc., Merck & Co., Inc., Neurim Pharmaceuticals Ltd, Novartis AG, Reviva Pharmaceuticals Inc., Shionogi & Co., Ltd. and Takeda Pharmaceutical Company Limited. Drug Profiles mentioned in this research are (diphenhydramine + lorazepam + zolpidem tartrate), ACT-541468, CB-2810, DORA-12, Drug for Insomnia, Drugs to Inhibit Angiotensin II Receptor Type 1 for Insomnia, EVT-201, HTL-6641, ITI-007, JNJ-42847922, JNJ-48816274, LASSBio-785, LASSBio-786, lemborexant, lorediplon, MK-8133, NEO-1940, piromelatine, ramelteon, S-117957, Small Molecule for Insomnia, Obesity and Treatment Resistant Depression, Small Molecule to Antagonize Orexin Receptor Type 1 and 2 for Insomnia, Small Molecule to Inhibit OX2R for Insomnia, Small Molecules to Activate CYP1A2 for Insomnia and Anxiety, UCM-765, zaleplon and zolpidem tartrate.
Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=747733 .
The Insomnia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 9, 3, 6 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively. Insomnia.
Insomnia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Insomnia and reviews pipeline therapeutics for Insomnia by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Insomnia therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Insomnia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Insomnia.
Explore more reports on Pharmaceuticals .
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
2nd floor, metropole, Next to inox theatre, Bund garden road,
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
SOURCE ReportsnReportsPR Newswire
Last updated on: 16/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.